Autolus Therapeutics Ltd reported $28.64M in Cost of Sales for its fiscal quarter ending in September of 2025.





Cost Of Sales Change Date
AstraZeneca USD 3.27B 471M Dec/2025
Autolus Therapeutics Ltd USD 28.64M 3.73M Sep/2025
Hikma Pharmaceutical USD 959M 492.5M Dec/2025
Novartis USD 3.54B 3M Dec/2025
Roche Holding CHF 8.48B 4.61B Dec/2025
Silence Therapeutics USD 12K 52K Dec/2025